Structure via PubChem · Public domain (PubChem)
talazoparib
Sign in to saveAlso known as BMN-673, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one
Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. It is an orally available poly ADP ribose polymerase (PARP) inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib.
In the Vinony graph
Vinony's link graph records 6 inbound references to talazoparib, and connects out to chemotherapy, tiazofurin and feces.
It is catalogued under topics including 4-Fluorophenyl compounds, Antineoplastic drugs and Chemicals using indexlabels.
Vinony links it to 7 Wikipedia language editions.
Chemical data
- Formula
- C19H14F2N6O
- Molecular weight
- 380.4 g/mol
- IUPAC name
- (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1(13),5,7,9-tetraen-4-one
- SMILES
- CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
- InChIKey
- IUEWAGVJRJORLA-HZPDHXFCSA-N
- XLogP
- 1.4
- Polar surface area
- 84.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2018
- Admin. routes
- oral
- Indications
- breast neoplasm, acute myeloid leukemia, neoplasm, squamous cell lung carcinoma
via ChEMBL · EBI
Research
701 papers- Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023
- Talazoparib.2012
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.The New England journal of medicine · 2018
- First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.Nature medicine · 2024
- Talazoparib.2006
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 380.1197
Show 4 more facts
- chemical formula
- C₁₉H₁₄F₂N₆O
- canonical SMILES
- CN1C(=NC=N1)C2C=3C4=C(C=C(C=C4NC2C5=CC=C(C=C5)F)F)C(=O)NN3
- isomeric SMILES
- CN1C(=NC=N1)[C@H]2C=3C4=C(C=C(C=C4N[C@@H]2C5=CC=C(C=C5)F)F)C(=O)NN3
- subject has role
- PARP inhibitor
Sources (5)
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Side effects
- Interactions
- Mechanism of action
- History
- Society and culture
- Economics
- References
Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. It is an orally available poly ADP ribose polymerase (PARP) inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib.
The most common adverse reactions of any grade were fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetite.
Excerpted from Wikipedia’s “talazoparib” article, available under the CC BY-SA 4.0 licence.